Prana Biotechnology Ltd. (PRAN) Receives Approval to Proceed with Alzheimer’s Clinical Trial

Yesterday, Prana Biotechnology announced that the company had received a recommendation that it should proceed as planned in its IMAGINE clinical trial (using PBT2) for Alzheimer’s. This recommendation came from the Data Safety Monitoring Board, an independent review group for clinical trials.

Prana is focused on commercializing research in age-related neurodegenerative disorders, and the discovery of its technology has been contributed by researchers from such institutes as The University of Melbourne, The Mental Health Research Institute (Melbourne), and Massachusetts General Hospital (a teaching hospital of Harvard Medical School).

In IMAGINE, a double-blind placebo controlled trial is being used to test the effects of PBT2 on specific areas of the brain in Alzheimer’s patients, including its effect on amyloid deposits in the brain (using PiB-PET scanning) and effects on increasing brain activity (FDG PET). A previous trial of PBT2 showed an improvement in the cognition of Alzheimer’s patients. Prana hopes that the testing will prove PBT2 is a safe treatment for the disease.

In addition to the IMAGINE test, Prana is conducting a separate six month PBT2 trial in 100 patients with early to mid-stage Huntington disease; the company is anticipating PBT2 will also benefit Huntington patients the same way it benefits Alzheimer’s patients.

For further information, please visit www.pranabio.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html